<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04942548</url>
  </required_header>
  <id_info>
    <org_study_id>HS-3243 Keto</org_study_id>
    <nct_id>NCT04942548</nct_id>
  </id_info>
  <brief_title>Reverse HFpEF: Ketogenic Reversal of Heart Failure With Preserved Ejection Fraction Study</brief_title>
  <official_title>Reverse HFpEF: Ketogenic Reversal of Heart Failure With Preserved Ejection Fraction Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a prospective pilot study utilizing the intervention of a medically&#xD;
      supervised, registered nurse and registered diabetes educator coached low-carbohydrate,&#xD;
      ketogenic diet to examine the impact it has as a treatment for heart failure with preserved&#xD;
      ejection fraction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">February 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MLHFQ Questionnaire</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in score on the Minnesota Living with Heart Failure Quality of Life (MLHFQ) Questionnaire for the HFpEF cohort.&#xD;
Max. Score = 105&#xD;
Min. Score = 0&#xD;
A reduced score means improvement of heart failure symptoms; better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PAH-SYMPACT Questionnaire</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in score on the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire for the PH-HFpEF cohort.&#xD;
Max. Score = 89&#xD;
Min. Score = 0&#xD;
A reduced score means improvement of pulmonary hypertension heart failure symptoms; better outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Weight</measure>
    <time_frame>6 Months</time_frame>
    <description>Weight in kilograms (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Glucose</measure>
    <time_frame>6 Months</time_frame>
    <description>Glucose in milligrams per deciliter (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Insulin</measure>
    <time_frame>6 Months</time_frame>
    <description>Insulin in microinternational unit per milliliter (uIU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)</measure>
    <time_frame>6 Months</time_frame>
    <description>Insulin and glucose are multiplied then divided by 405 to report HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Albumin</measure>
    <time_frame>6 Months</time_frame>
    <description>Albumin in grams per deciliter (g/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Bilirubin total</measure>
    <time_frame>6 Months</time_frame>
    <description>Bilirubin total in milligrams per deciliter (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Alanine Transaminase (ALT)</measure>
    <time_frame>6 Months</time_frame>
    <description>ALT in units per liter (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Aspartate Aminotransferase (AST)</measure>
    <time_frame>6 Months</time_frame>
    <description>AST in units per liter (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Alkaline Phosphatase (ALP)</measure>
    <time_frame>6 Months</time_frame>
    <description>ALP in units per liter (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: High Sensitivity C-Reactive Protein (HS-CRP)</measure>
    <time_frame>6 Months</time_frame>
    <description>HS-CRP in milligrams per deciliter (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Triglycerides</measure>
    <time_frame>6 Months</time_frame>
    <description>triglyceride in milligrams per deciliter (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: High Density Lipoprotein (HDL)</measure>
    <time_frame>6 Months</time_frame>
    <description>HDL in milligrams per deciliter (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Hemoglobin A1c</measure>
    <time_frame>6 Months</time_frame>
    <description>hemoglobin A1c in percent (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Health: Body Mass Index (BMI)</measure>
    <time_frame>6 Months</time_frame>
    <description>Weight and height will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical Function: 6 Minute Walk Test (6MWT)</measure>
    <time_frame>6 Months</time_frame>
    <description>6-minute walk test is reported in meters (m) of how far a subject walks in 6 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical Function: Maximum Oxygen Consumption (VO2max)</measure>
    <time_frame>6 Months</time_frame>
    <description>VO2 max is reported in liters per minute (L/min) while performing a cardiopulmonary exercise test (CPET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical Function: Maximum Work</measure>
    <time_frame>6 Months</time_frame>
    <description>Maximum work achieved while performing a cardiopulmonary exercise test (CPET) is reported in watts (W)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical Function: 30 Second Sit-to-Stand test (30s STS)</measure>
    <time_frame>6 Months</time_frame>
    <description>30s STS is reported in quantity of how many times the subject can come to a full stand from a seated position in 30 seconds (s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical Function: Leg Press - 1 Repetition Maximum</measure>
    <time_frame>6 Months</time_frame>
    <description>Leg press is reported in kilograms (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical Function: Chest Press - 1 Repetition Maximum</measure>
    <time_frame>6 Months</time_frame>
    <description>Chest press is reported in kilograms (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical Function: Leg Extension - 1 Repetition Maximum</measure>
    <time_frame>6 Months</time_frame>
    <description>Leg extension is reported in kilograms (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Remodeling: Changes in the Left Ventricle (LV) size</measure>
    <time_frame>6 Months</time_frame>
    <description>This is determined by the internal diameter measurement of the LV, reported in centimeters (cm) from a subject performed echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Remodeling: Changes in the Left Ventricle (LV) thickness</measure>
    <time_frame>6 Months</time_frame>
    <description>This is determined by a measurement of the LV wall, reported in millimeters (mm) from an echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Remodeling: Changes in the Left Ventricle (LV) mass</measure>
    <time_frame>6 Months</time_frame>
    <description>This is determined by a combination formula of the interventricular septum diastole (IVSd), left ventricle diastole (LVd), and posterior wall diastole (PWd), calculated by an echocardiogram and reported in grams (g).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Remodeling: Changes in Left Atrium (LA) size</measure>
    <time_frame>6 Months</time_frame>
    <description>This is determined by the internal diameter measurement of the LA, reported in centimeters (cm) from a subject performed echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Remodeling: Changes in Inferior Vena Cava (IVC) size</measure>
    <time_frame>6 Months</time_frame>
    <description>This is determined by the internal diameter perpendicular to the long axis of the IVC at the end-expiration, reported in centimeters (cm) from the echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Remodeling: Changes in estimated Right Atrial Pressure (RAP)</measure>
    <time_frame>6 Months</time_frame>
    <description>This is determined by a combination equation subtracting the venous return (VR) from the central venous pressure (CVP), reported in millimeters of mercury (mmHg) from the echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Remodeling: Changes in Right Ventricle Systolic Pressure (RVSP)</measure>
    <time_frame>6 Months</time_frame>
    <description>This estimates the pressure inside the artery that supplies the lung with blood, reported in millimeters of mercury (mmHg) from the echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the rate of mitral annulus velocity (e')</measure>
    <time_frame>6 Months</time_frame>
    <description>e' is reported in centimeters per second (cm/s) based on a subject performed echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the ratio of transmitral early peak velocity (E) by pulsed wave Doppler over e' (E/e')</measure>
    <time_frame>6 Months</time_frame>
    <description>E/e' is reported as an integer based on the transmitral early peak velocity (E) over the mitral annulus velocity (e') from a subject performed echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PH-HFpEF Only Hemodynamics: Changes in Right Atrial Pressure (RAP)</measure>
    <time_frame>6 Months</time_frame>
    <description>This is determined by a combination equation subtracting the venous return (VR) from the central venous pressure (CVP), reported in millimeters of mercury (mmHg) from the echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PH-HFpEF Only Hemodynamics: Changes in Pulmonary Artery Pressure (PAP)</measure>
    <time_frame>6 Months</time_frame>
    <description>This is calculated from systolic, by Tricuspid Regurgitation maximum (TRmax) and diastolic, by Pulmonary Regurgitation-end velocity (PR-end) pulmonary artery pressures, reported in millimeters of mercury (mmHg) from the echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PH-HFpEF Only Hemodynamics: Changes in Pulmonary Artery Occlusive Pressure (PAOP)</measure>
    <time_frame>6 Months</time_frame>
    <description>This is determined by the pressure value of the pulmonary artery once it's occluded during a Right Heart Catheterization (RHC), measured in millimeters of mercury (mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PH-HFpEF Only Hemodynamics: Changes in Pulmonary Vascular Resistance (PVR)</measure>
    <time_frame>6 Months</time_frame>
    <description>Left Atrial Pressure (LAP), Pulmonary Artery Pressure (PAP) and Cardiac Output (CO) are combined to report the PVR in Wood Units (WU) from a Right Heart Catheterization (RHC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PH-HFpEF Only Hemodynamics: Changes in Cardiac Output (CO)</measure>
    <time_frame>6 Months</time_frame>
    <description>Stoke Volume (SV) and Heart Rate (HR) are combined to report CO in liters per minute (L/min) from the right heart catheterization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PH-HFpEF Only Hemodynamics: Changes in Cardiac Index (CI)</measure>
    <time_frame>6 Months</time_frame>
    <description>Cardiac Output (CO) and Body Surface Area (BSA) are combined to report CI in liters per minute per meters squared (L/min/m^2) from a Right Heart Catherization (RHC).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>HFpEF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed with obesity related heart failure with preserved ejection fraction(HFpEF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH-HFpEF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed with obesity related pulmonary hypertension heart failure with preserved ejection fraction (PH-HFpEF)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ketogenic Diet</intervention_name>
    <description>Ketogenic diet intervention that is high in fat and low in carbohydrates, causing the body to induce a state of metabolic ketosis, whereby fat is broken down into ketones to provide an energy source for the body.</description>
    <arm_group_label>HFpEF</arm_group_label>
    <arm_group_label>PH-HFpEF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (age 21-80) who meet clinical signs and symptoms of heart failure based on&#xD;
             clinical assessment.&#xD;
&#xD;
          -  The subject must meet at least one of the following hemodynamic criteria for HFpEF of&#xD;
             PH-HFpEF by right heart catheterization (RHC) within 6 months of screening visit;&#xD;
&#xD;
        A) HFpEF:&#xD;
&#xD;
          1. At rest: mean pulmonary artery occlusions pressure (PAOP) &gt; 15, pulmonary vascular&#xD;
             resistance (PVR) &lt; 3 Wood Units, or&#xD;
&#xD;
          2. HFpEF with fluid challenge, defined as increase in PAOP post 500 cc fluid bolus: mean&#xD;
             PAOP &gt; 18, PVR &lt; 3 Wood Units, or&#xD;
&#xD;
          3. HFpEF with exercise, defined as peak mean PAOP &gt; 17, PVR &lt; 3 Wood Units if age &lt; 50 or&#xD;
             peak mean PAOP &gt; 19 and PVR &lt; 3 Wood Units if age &gt;= 50&#xD;
&#xD;
        B) PH-HFpEF:&#xD;
&#xD;
          1. At rest: mean pulmonary artery occlusion pressure (PAOP) &gt; 15, mean pulmonary artery&#xD;
             pressure (PAP) &gt;= 25, pulmonary vascular resistance (PVR) &gt; 3 Wood Units, or&#xD;
&#xD;
          2. PH-HFpEF with fluid challenge, defined as increase in PAOP post 500 cc fluid bolus:&#xD;
             mean PAOP &gt; 18, mean PAP &gt;= 25, PVR &gt; 3 Wood Units, or&#xD;
&#xD;
          3. PH-HFpEF with exercise, defined as peak mean PAOP &gt; 17, peak mean PAP &gt; 30, peak PVR &gt;&#xD;
             1.34 Wood Units if age &lt; 50 or peak mean PAOP &gt; 19, peak mean PAP &gt; 33, and PVR &lt; 2.1&#xD;
             Wood Units if age &gt;= 50&#xD;
&#xD;
               -  The subject also must meet criteria for metabolic syndrome, defined as: Abdominal&#xD;
                  obesity (BMI &gt; 30 kg/m2 or abdominal obesity, waist circumference &gt; 102 cm men, &gt;&#xD;
                  88 cm women) AND 2 of the following;&#xD;
&#xD;
        a. Currently being treated for systemic hypertension or blood pressure (BP) &gt;= 135/85 b.&#xD;
        Glucose intolerance with diagnosis of type 2 diabetes, or fasting blood glucose 110-125&#xD;
        mg/dL or hemoglobin A1c &gt; 6% c. Triglycerides &gt;= 150, or on treatment for high&#xD;
        triglycerides d. HDL &lt; 40 men, &lt; 50 women, or on treatment for high triglycerides&#xD;
&#xD;
          -  If the subject is on pulmonary hypertension specific vasodilators, they must be on&#xD;
             stable medical therapy without changes to pulmonary vasodilator medication within 3&#xD;
             months prior to screening visit.&#xD;
&#xD;
          -  The subject must have also had a cardiopulmonary exercise test within 6 months of&#xD;
             screening visit.&#xD;
&#xD;
          -  The subject must have also had an echocardiogram within 6 months of screening visit.&#xD;
&#xD;
          -  The subject must have demonstrated stable weight (less that 5% weight loss) 3 months&#xD;
             prior to screening visit. (They cannot already be losing weight).&#xD;
&#xD;
          -  The subject owns and uses a smartphone or tablet.&#xD;
&#xD;
          -  Must speak English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is already on a significant weight loss trajectory prior to study entry.&#xD;
&#xD;
          -  The subject cannot be on an alternative diet plan or strategy (e.g., Weight Watchers,&#xD;
             Nutrisystem, Ornish).&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50%.&#xD;
&#xD;
          -  Severe valvular disease by echocardiogram or dysfunctional prosthetic valve.&#xD;
&#xD;
          -  Active pericardial disease (moderate or large pericardial effusion or constrictive&#xD;
             pericarditis).&#xD;
&#xD;
          -  Active coronary ischemia defined by abnormal stress test, angiogram, or coronary CT&#xD;
             angiography per investigator.&#xD;
&#xD;
          -  Prolonged corrected QT interval (QTc) &gt; 450 ms&#xD;
&#xD;
          -  Significant lung disease on pulmonary function tests (PFT's) within the 6 months of&#xD;
             screening visit, (Both post-bronchodilator values and pre-bronchodilator values must&#xD;
             meet exclusion criteria. If either post- or pre-bronchodilator values do not, the&#xD;
             subject may be included) defined as either:&#xD;
&#xD;
               1. Irreversible obstructive airways disease (post-bronchodilator forced expiratory&#xD;
                  volume/forced vital capacity (FEV1/FVC) &lt; 70% predicted) or&#xD;
&#xD;
               2. Restrictive lung disease (FVC &lt; 70% predicted. If total lung capacity (TLC) is &gt;=&#xD;
                  70%, it is acceptable to have an FVC of &lt; 70%) or&#xD;
&#xD;
               3. More than mild radiographic pulmonary disease as determine don CT scan within the&#xD;
                  past 2 years per investigator.&#xD;
&#xD;
          -  History of non-adherence to diuretics within 3 months of screening visit.&#xD;
&#xD;
          -  History or recurrent severe hypokalemia, potassium &lt; 3.0 mg/dL.&#xD;
&#xD;
          -  History of kidney stones, gout, or gallbladder disease unless in the opinion of the&#xD;
             investigator it will not impact the safety of the patient&#xD;
&#xD;
          -  C-peptide &lt; 0.5 ng/mL (increased risk of diabetic ketoacidosis (DKA))&#xD;
&#xD;
          -  Uncorrected anemia (hemoglobin &lt; 10 g/dL).&#xD;
&#xD;
          -  Unable to participate in the comprehensive ketogenic diet program, including biometric&#xD;
             data acquisition and data entry (glucometer self-stick and smartphone use).&#xD;
&#xD;
          -  Unable or unwilling to prepare meals for self.&#xD;
&#xD;
          -  Unable to perform quantitative cardia testing regimen (cardiopulmonary exercise&#xD;
             testing, 6-minute walk).&#xD;
&#xD;
          -  Subject is pregnant or planning to become pregnant in the next 14 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas C Waliczek</last_name>
    <phone>303-270-2844</phone>
    <email>Waliczekt@njhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Jewish Health and University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas C Waliczek</last_name>
      <phone>303-270-2844</phone>
      <email>Waliczekt@njhealth.org</email>
    </contact>
    <investigator>
      <last_name>Darlene Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Kim</last_name>
      <phone>303-270-2755</phone>
      <email>KimD@njhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Darlene Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>obese</keyword>
  <keyword>keto</keyword>
  <keyword>diet</keyword>
  <keyword>cardiac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

